Technology Innovation Institute Completes Asteroid-Landing Probe for Landmark Emirates Mission to the Asteroid Belt

 In a first-of-its-kind mission, TII’s probe aboard the MBR Explorer will journey past six asteroids in the main belt before landing on 269 Justitia, making it only the seventh asteroid in history to be reached on its surface by a probe

Designed, built and tested in Abu Dhabi, TII’s probe is the mission’s only deployable payload, operating fully autonomously around and on Justitia

Thought to have formed in the distant Kuiper Belt in the outer Solar System, 269 Justitia may preserve clues to how water and organic material were distributed during the formation of the planets

Watch the EMA hero film here

 

The Technology Innovation Institute (TII) has revealed the UAE-built probe it has developed for the Emirates Mission to the Asteroid Belt (EMA). The probe will soon travel to Colorado, USA, for final integration with the MBR Explorer spacecraft ahead of its planned 2028 launch. In a historic first, TII’s probe will image two planets and seven asteroids — flying past six asteroids in the main belt before culminating in a rendezvous with and landing on the seventh, 269 Justitia. If successful, the landing will make Justitia only the seventh asteroid in history to be reached on the surface by the probe.  

Designed, built and tested end-to-end in Abu Dhabi by TII’s Propulsion and Space Research Center, in collaboration with the UAE Space Agency, as well as HEX20, Khalifa University and UAE University’s National Space Science and Technology Center, the TII-built probe is the mission’s only deployable payload. It will separate from MBR Explorer to make contact with Justitia’s surface at the furthest point of the mission and operate fully autonomously in deep space, capturing close-range images and excavating its surface to provide new insights into its composition and physical characteristics. 269 Justitia is thought to have formed in the Kuiper Belt before migrating into the main asteroid belt during the early formation of the Solar System.

H.E. Faisal Al Bannai, Secretary General, Advanced Technology Research Council, the Abu Dhabi Government entity overseeing TII, and Member of the UAE Supreme Space Council, said: “If you want to build serious technological capability, you take on a problem that forces you to push further. For this mission, that means a probe that must make decisions and operate on its own in deep space. And our teams have built that technology here in the UAE. The mission might still be ahead, but we have already expanded what we know how to build. That is how sovereign capability grows. We solve a difficult problem, then set our sights on a bigger one.”

269 Justitia is among the reddest bodies ever observed in the main asteroid belt. Its spectrum more closely resembles objects in the Kuiper Belt beyond Neptune than neighboring asteroids, suggesting it may have formed in the cold outer Solar System, beyond the distance at which methane and methanol freeze, before migrating inward early in the Solar System’s history to its current orbit in the main asteroid belt.  Its surface is thought to be covered in complex organic material produced by the irradiation of that ice. Reaching such a body without a decade-long voyage to the Kuiper Belt itself gives the international scientific community access to material that is otherwise far beyond practical reach, and to evidence bearing on how water and volatiles were distributed as the planets formed.

Dr. Najwa Aaraj, Chief Executive Officer, TII, said: “EMA Probe demonstrates what becomes possible when advanced research is translated into mission-ready engineering. Our teams at TII have developed a system designed to withstand extreme conditions, operate with exceptional precision, and deliver meaningful science billions of kilometers from Earth. The mission reflects not only the caliber of our talent, but the depth of scientific and engineering capability the UAE has built to contribute to some of the world’s most ambitious space missions.”

The MBR Explorer spacecraft will travel approximately 5 billion kilometers over eight years, using gravity-assist maneuvers at Venus, Earth and Mars, and conducting close encounters with six asteroids before arriving at 269 Justitia. The spacecraft is scheduled to launch from Japan in March 2028 within a narrow three-week launch window aligned to interplanetary conditions. Because the spacecraft itself cannot safely approach within a few kilometers of the surface, the probe will separate, make contact with the surface, and deliver the mission’s closest observations.

Dr. Elias Tsoutsanis, Chief Researcher, Propulsion and Space Research Center, TII, said: “The engineering challenge is not simply reaching Justitia, but ensuring the probe can survive an eight-year journey and still perform precisely when it matters most. Every element – from the hardware and thermal design to the onboard software – has been engineered and tested for that final encounter.”

The probe operates fully autonomously throughout its mission, receiving no command from Earth or the MBR Explorer spacecraft after launch. Its onboard software determines when to image, how many images to capture, and which are worth keeping, a capability that rests on the digital processing unit designed and developed by TII – the board that handles the probe’s processing, image selection and power management. The probe does not wait until reaching Justitia to begin; it images throughout the cruise alongside the spacecraft’s other payloads, transmitting data back at approximately six-month intervals. Two cameras, one wide-field and one narrow-field, cover both context and high-resolution data.  

Dr. Anton Ivanov, Principal Investigator and Executive Director, Propulsion and Space Research Center, TII, said: “What makes this probe distinctive is the level of independence engineered into such a compact system. Once deployed, it must sense, decide and operate on its own, far beyond Earth. The program has also helped train Emirati engineers and strengthen the advanced capabilities needed to build a globally competitive space technology ecosystem in the UAE.”

On arrival, the MBR spacecraft will spend approximately seven months in orbit around Justitia, beginning at 250 kilometers and descending through a series of lower orbits. The probe will deploy during a low-altitude pass in early 2036, then descend and make contact with the surface, imaging continuously and transmitting to the spacecraft above. The subsequent images will then allow scientists to study material beneath the surface layer that cannot be characterized from orbit.

EMA is the UAE’s second interplanetary mission and the first in which the spacecraft element has been designed, engineered, assembled and tested within the country. The mission sits within a broader national commitment to the sector. In May 2026, the Supreme Space Council approved a AED 1 billion International Space Cooperation Program intended to connect UAE research institutions with counterparts internationally, localize advanced space technologies, and develop Emirati talent, in support of the National Space Strategy 2031.

For more information, visit www.tii.ae 

Permalink

https://www.aetoswire.com/en/news/tii02102026e

Contacts

Thushara Mohanan, thushara.mohanan@tii.ae

LTM Launches BlueVerse™ AgenTraceIQ

 MUMBAI, India - Monday, 05. October 2026

Offering stems from Rubrik’s Project Hourglass, an alliance helping organizations scale agentic AI securely

 

(BUSINESS WIRE)--LTM, the Business Creativity partner to the world's largest enterprises, today announced the launch of BlueVerse™ AgenTraceIQ, an offering designed to help organizations securely adopt and scale agentic AI. Combining Rubrik Agent Cloud with LTM's AI governance and managed services expertise, the offering enables organizations to monitor AI agents, establish guardrails, and rewind unintended agent actions across business-critical environments.

As part of Rubrik’s Project Hourglass, LTM and other elite Global Systems Integrators partner with Rubrik, the Security and AI Operations Company, to deliver Rubrik Agent Cloud for Anthropic's Claude Code to their enterprise clients. The collaboration strengthens the ability for organizations to adopt agentic systems with the necessary security, governance, and resilience at scale.

"As AI agents increasingly act autonomously, the stakes for enterprise security and resilience have never been higher. Together with LTM, we are empowering organizations to move from reactive risk management to a proactive, secure framework, ensuring they can innovate with AI at speed without compromising their operational integrity." — Alok Agrawal, Chief Solutions Officer, Rubrik.

As AI agents become increasingly embedded in enterprise operations, organizations need a structured approach to managing risk, accountability, and operational continuity. Scaling beyond experimentation requires greater oversight of agent behaviour, stronger policy enforcement, and the ability to respond quickly when unexpected outcomes occur.

BlueVerse™ AgenTraceIQ addresses these challenges through an integrated framework that combines agent observability, governance, and resilience. Powered by Rubrik Agent Cloud and operationalized through LTM's governance-led services model, the offering brings together enterprise-ready advisory, deployment, and managed services to support responsible AI adoption at scale.

The solution provides continuous visibility into agent activity, enforces policy-driven controls and zero-trust access, and enables rapid restoration of systems, data, configurations, and repositories following unintended or destructive actions. By linking agent actions to prompts, plans, and tool interactions, it enhances explainability, auditability, and root-cause analysis. BlueVerse™ AgenTraceIQ supports leading agent ecosystems, including Microsoft Copilot Studio, Salesforce Agentforce, Amazon Bedrock, Anthropic Claude, and custom-built frameworks.

"Agentic AI is rapidly reshaping enterprise operations, but scaling adoption requires more than deploying intelligent agents. Organizations need the ability to understand agent behaviour, establish accountability, and respond quickly when unexpected outcomes occur. Together with Rubrik, BlueVerse™ AgenTraceIQ helps enterprises move from experimentation to trusted, production-scale AI operations," said Krishnan Iyer, Chief Growth Officer, LTM.

The offering also includes AI Resilience Assessments, Governance Framework Design, Deployment & Integration Services, and Managed Governance Operations, helping organizations establish enterprise-ready operating models for agentic AI. By combining Rubrik's technology with LTM's AI transformation expertise, BlueVerse™ AgenTraceIQ enables organizations to accelerate adoption, strengthen compliance readiness, and improve operational certainty as AI becomes embedded across the business.

To learn more about BlueVerse™ AgenTraceIQ , click here.

About LTM

LTM — a Larsen & Toubro Group Company — is an AI-centric global technology services company and the Business Creativity partner to the world’s largest enterprises. We bring human insights and intelligent systems together to help clients create greater value at the intersection of technology and domain expertise. Our capabilities span integrated operations, transformation and business AI — enabling new ways of working, new productivity paradigms and new roads to value. Together with over 87,000 employees across 40 countries and our global network of partners, LTM owns outcomes for clients, helping them not just outperform the market, but Outcreate it. Read more at LTM.com.

RUBRIK® and the Rubrik logo are registered trademarks of Rubrik, Inc.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260925050912/en/

Permalink

https://www.aetoswire.com/en/news/54610941

Contacts

Media Contact: Gitanjali Sreepal | Global Media Relations | gitanjali.sreepal@ltm.com

JEOL: Sales launch of HAXIS: The New Low-angle Ion Milling Scanning Electron Microscope

 

TOKYO -

(BUSINESS WIRE) -- JEOL Ltd. (President & CEO Izumi Oi) announces the development of its new low‑angle ion‑milling scanning electron microscope, HAXIS, and will commence sales on October 5, 2026.

HAXIS Low-angle Ion Milling Scanning Electron Microscope

Background of development

As advanced semiconductor device structures continue to shrink and grow more complex, it has become difficult to contact and measure microscale circuits using nano-manipulators. In addition, contact caused by probing may affect the analysis target, necessitating new failure analysis methods.

JEOL has conducted long-term research on the passive voltage contrast (PVC) detection technology and established a method for stable, highly reproducible PVC observation technology through the advancement of detectors and sample preparation techniques.

HAXIS is JEOL's new semiconductor failure analysis platform that combines such technologies.

It has realized clear and highly reproducible PVC observation even with advanced semiconductors. By visually detecting electrical anomalies while minimizing the effects of processing damage and contamination, it is possible to efficiently identify the defect location and determine the cause. The use of argon (Ar), an inert gas, ensures stable surface quality and reduces running costs.

The quality of PVC observation is significantly affected by the surface condition of the sample after delayering. HAXIS uses a unique Low-Angle Ion Milling (LIM) delayering technique using Ar ion beams to create a flat surface with minimal damage to the sample surface. This enables clear and highly reproducible PVC observation while retaining structure and potential information even in advanced devices.

Semiconductor failure analysis involves multiple steps, from defect localization to physical analysis and root-cause investigation. As device complexity increases, shortening the turnaround time from failure detection to actionable results becomes increasingly critical.

HAXIS introduces a new approach to failure localization by integrating LIM delayering with SEM imaging and passive voltage contrast (PVC) analysis. This combined workflow enables rapid and highly accurate identification of failure locations, supporting QTAT (Quick Turnaround Time) failure analysis and accelerating the transition from electrical failure detection to physical analysis and root-cause identification.

Main features

Clear PVC imaging

Cost effective Ar processing

Damageless Delayering with LIM

Layer-by-layer LIM / PVC Analysis

Contamination free transfer

Sales target

15 units / year

Product Overview

HAXIS LIM-SEM Multi Beam System

https://www.jeol.com/products/scientific/sem/haxis.php

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260928207899/en/

Permalink

https://aetoswire.com/en/news/0510202657797

Contacts

JEOL Ltd.

3-1-2, Musashino, Akishima, Tokyo, 196-8558, Japan

Izumi Oi, President & CEO

(Stock code: 6951, Tokyo Stock Exchange Prime Market)

https://www.jeol.com/

JEOL Ltd.

SI Sales Division

webmaster@jeol.co.jp

https://www.jeol.com/contacts/products.php

 

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

 LEXINGTON, Mass. - Monday, 05. October 2026 AETOSWire  

Survival estimate remained at 48% between years two and three, extending evidence of durable benefit

Results observed in heavily pretreated, difficult-to-treat population that received a median of four prior lines of therapy; nearly three-quarters of patients had platinum-resistant or refractory cancer

 

(BUSINESS WIRE) -- Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada.

Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive and off all therapy.

These results come from a population with substantial prior treatment. Patients had received a median of four prior lines of therapy, and 66% had received at least four. All had previously received platinum chemotherapy, 77% had received bevacizumab and 57% had received a PARP inhibitor. Nearly three-quarters had platinum-resistant or refractory disease, meaning their cancer had progressed during platinum treatment or returned within six months of it.

“In recurrent ovarian cancer, conventional checkpoint immunotherapy has rarely produced lasting benefit, particularly after the disease stops responding to platinum chemotherapy,” said Rebecca L. Porter, MD, of Dana-Farber Cancer Institute, who presented the data. “What stands out with longer follow-up is the survival plateau in patients who had already received multiple treatments. That pattern suggests that a different approach to activating the immune system may offer some patients lasting benefit, even when treatment options have narrowed.”

Three-year follow-up findings

Overall efficacy results (n=35)

Overall survival (OS): Estimated survival was 48% at both two and three years. Median OS was 14.8 months.

Objective response rate (ORR): 23% of patients (8/35) had a response, including one complete response and seven partial responses.

Duration of response: Responses lasted a median of 9.7 months.

Clinical benefit: 31% of patients (11/35) had a response or stable disease lasting at least 24 weeks.

Alive and off treatment: At last follow-up, 25% (11 of all 44 patients who received at least one dose of treatment) were alive and off all therapy.

Results by patient subgroup

Platinum-resistant or refractory disease (n=25): Estimated three-year survival was 47%. ORR was 20% (5/25), including one complete and four partial responses.

Platinum-sensitive disease (n=10): Estimated three-year survival was 45%. Thirty percent (3/10) of patients had a partial response.

Four or more prior lines of therapy (n=23): Estimated three-year survival was 48%. ORR was 17% (4/23), with all four responses being partial responses.

Disease progression on a PARP inhibitor (n=17): In patients whose cancer had progressed during PARP inhibitor treatment or maintenance, estimated three-year survival was 61%. Two patients (12%) had partial responses.

Safety remained consistent with the known BOT+BAL profile. No new safety signals or treatment-related deaths were reported.

“The most compelling finding is that the survival curve extends beyond two years in women who had already received multiple treatments, including those with platinum-resistant or refractory disease,” said Steven J. O’Day, MD, Chief Medical Officer of Agenus. “We have seen a similar pattern of durable survival in other difficult-to-treat cancers studied with BOT+BAL. This three-year ovarian update strengthens our conviction that the combination can deliver meaningful, lasting benefit to a subset of patients who have had few effective immunotherapy options.”

The three-year ovarian results add to a pattern of long-term survival across difficult-to-treat cancers studied with BOT+BAL. In the broader 400+ patient Phase 1b pan-tumor analysis, estimated two-year survival was 39%. In a separate cohort of patients with refractory MSS metastatic colorectal cancer without active liver metastases, estimated survival was 41% at two years and 33% at three years. These findings are particularly notable in cancers where conventional immunotherapy has historically offered limited benefit.

The consistent and durable BOT+BAL activity in heavily pretreated cancers that are poorly immunogenic or resistant to prior immunotherapy, reinforced by deep pathologic responses in neoadjuvant studies, strengthens the rationale for moving treatment earlier in the course of disease. Before surgery, when the primary tumor and surrounding lymph nodes remain intact, BOT+BAL may have the greatest opportunity to generate lasting antitumor immunity, reduce recurrence and ultimately increase the number of patients who may be cured.

The full presentation can be found on the publications section of the Agenus website at www.agenusbio.com/publications.

BOT and BAL are in development and have not been approved by the U.S. Food and Drug Administration.

Presentation details

Abstract Title: Next Generation Immune Checkpoint Inhibition with Botensilimab Plus Balstilimab in Recurrent Ovarian Cancer: Results by Platinum Sensitivity Status and 3-Year Overall Survival

Presenter: Rebecca L. Porter, MD; Dana-Farber Cancer Institute, Boston, MA, USA

Poster Presentation number: 969

Session Title: Poster Rounds with Professors Session, Ovarian Cancer 03 Session

Date/Time: Saturday, October 3, 2026 | 10:50am-10:55am EDT

About the C-800-01 Study

C-800-01 (NCT03860272) is a multicenter Phase 1b trial evaluating BOT with or without BAL in advanced solid tumors. The ovarian cancer cohort included patients with recurrent disease for whom no standard therapy was available or whose cancer had progressed after standard treatment. The efficacy analysis included 35 patients who had at least one tumor scan after starting therapy. The safety population included all 44 patients who received treatment. The data cutoff for this analysis was December 13, 2025.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

Agenus’ Commitment to Patient Access

Until marketing authorization is granted, BOT+BAL is accessible only through clinical trials and authorized early access mechanisms where permitted and available under each country’s regulatory framework. For eligible French patients treated in hospitals under AAC and meeting the predefined criteria, BOT+BAL is fully reimbursed by France’s national health system. Outside France, access may be available in select countries through paid named-patient programs, which may involve out-of-pocket costs to the patient or coverage under applicable national or private reimbursement arrangements. These programs are physician-driven and are not promotional.

About Botensilimab (BOT)

Botensilimab (BOT) is a human multifunctional, Fc-enhanced anti-CTLA-4 antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to “cold” tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. BOT augments immune responses across a wide range of tumor types by priming and activating T cells, reducing intratumoral regulatory T cells, activating myeloid cells and inducing durable memory responses.

Approximately 1,500 patients have been treated with BOT and balstilimab (BAL) in phase 1 and phase 2 clinical trials. The combination with Agenus’ investigational PD-1 antibody, BAL, has shown clinical responses across more than nine cancers. For more information about BOT trials, visit www.clinicaltrials.gov.

About Balstilimab (BAL)

Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in more than 900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "forecasts," "estimates," "will," “establish,” “potential,” “superiority,” “best in class,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2025, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261003256338/en/

Permalink

https://www.aetoswire.com/en/news/0510202657782

Contacts

Investors

917-362-1370 | investor@agenusbio.com

Media

781-674-4422 | communications@agenusbio.com

Venture Global and ConocoPhillips Announce 20-Year LNG Sales and Purchase Agreement

 ARLINGTON, Va. - 

(BUSINESS WIRE) -- Today, Venture Global, Inc. (NYSE: VG) and ConocoPhillips (NYSE: COP) announced a new, long-term Sales and Purchase Agreement (SPA) for liquefied natural gas (LNG). Under the SPA, ConocoPhillips will buy 1.0 million tonnes per annum (MTPA) of LNG from Venture Global for 20 years, starting in 2030.

"Venture Global is proud to welcome ConocoPhillips, one of the world's leading energy companies, as a long-term partner," said Venture Global CEO Mike Sabel. "This agreement reflects continued market confidence in our proven ability to deliver reliable, low-cost U.S. LNG quickly and at scale. We look forward to supporting ConocoPhillips' growing global LNG portfolio for decades to come."

About Venture Global

Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (LNG) with over 100 MTPA of capacity in production, construction, or development. Venture Global began producing LNG from its first facility in 2022 and is now one of the largest LNG exporters in the United States. The company’s vertically integrated business includes assets across the LNG supply chain including LNG production, natural gas transport, shipping and regasification. The company’s first three projects, Calcasieu Pass, Plaquemines LNG, and CP2 LNG, are located in Louisiana along the Gulf of America. Venture Global is developing carbon capture and sequestration projects at each of its LNG facilities.

Forward-Looking Statements

This press release contains certain statements that may include “forward-looking statements.” All statements, other than statements of historical or present facts or conditions, included herein are “forward-looking statements.” Included among “forward-looking statements” are, among other things, statements regarding Venture Global’s business strategy, plans and objectives. Venture Global believes that the expectations reflected in these “forward-looking statements” are reasonable, however they are inherently uncertain and involve a number of risks and uncertainties beyond Venture Global’s control. In addition, assumptions may prove to be inaccurate. Actual results may differ materially from those anticipated or implied in “forward-looking statements” as a result of a variety of factors. These “forward-looking statements” speak only as of the date made, and other than as required by law, Venture Global undertakes no obligation to update or revise any “forward-looking statement” or provide reasons why actual results may differ, whether as a result of new information, future events or otherwise.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261001098196/en/

Permalink

https://www.aetoswire.com/en/news/0210202657758

Contacts

Investor Contact:

Ben Nolan

IR@ventureglobalLNG.com

Media Contact:

Shaylyn Hynes

press@ventureglobalLNG.com

NIQ Brings New AI and Automation Capabilities to Retail Space Planning and Merchandising

 

New AI and automation capabilities help retailers close execution gaps and scale merchandising decisions across every store.

 

(BUSINESS WIRE)--NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced new AI and automation capabilities for NIQ Spaceman®, its retail space planning and merchandising platform trusted by more than 600 retailers across 65+ countries. The enhancements help retailers create store-specific planograms up to 50 times faster, identify execution and compliance gaps, and scale merchandising decisions across their store networks through expanded cloud-based access.

"Retailers are under increasing pressure to localize assortments, execute consistently across stores, and respond more quickly to changing shopper behavior," said Natalie Williams, SVP, Product at NIQ. "These enhancements help simplify that process by embedding agentic AI directly into merchandising workflows and automating traditionally manual planning tasks. That means teams can spend less time building and updating planograms and more time acting on opportunities. With greater automation, retailers can improve productivity, respond faster to change, and make more confident merchandising decisions at scale."

Key client benefits

Work more efficiently with NIQ Optiq: Use conversational AI to create and optimize planograms through natural-language requests within Spaceman, reducing manual effort and helping merchandising teams complete traditionally time-intensive planning tasks more efficiently.

Localize store-specific planograms at scale: Use Spaceman’s automation capabilities to create and maintain store-specific planograms across large store networks, accounting for local market conditions, assortments, and shopper behavior to bring greater localization to the shelf at scale.

Improve execution through AI-powered compliance measurement: Automatically identify execution gaps and compliance issues across stores, reducing manual audits and driving a more consistent shopper experience.

These investments reflect NIQ's broader commitment to embedding trusted AI across retail workflows and delivering cloud-enabled solutions that help retailers move more seamlessly from planning to execution. By connecting intelligent automation, merchandising decisions, and execution measurement, NIQ is helping retailers drive greater efficiency, consistency, and business impact across their operations.

About NIQ

NielsenIQ (NYSE: NIQ) is a leading consumer intelligence company, delivering the most complete and trusted understanding of consumer buying behavior and revealing new pathways to growth. By combining an unmatched global data footprint and granular consumer and retail measurement with decades of AI modeling expertise, NIQ builds decision systems that help companies turn complex data into confident action.

With operations in more than 90 countries, NIQ covers approximately 82% of the world’s population and more than $7.4 trillion in global consumer spend. Through cloud-based platforms, advanced analytics and AI-driven insights, NIQ delivers The Full View™—helping brands and retailers understand what consumers buy, why they buy it, and what to do next.

For more information, please visit www.niq.com.

Spaceman® and NIQ® are registered trademarks (NIQ with additional pending applications); NIQ Optiq and The Full View™ are pending trademarks; all of Nielsen Consumer LLC or its affiliates. NielsenIQ® is a registered trademark licensed to NIQ. All other trademarks are the property of their respective owners.

Forward-Looking Statements

This press release may contain forward-looking statements regarding anticipated timelines, benefits, features, and outcomes of the latest Spaceman enhancements. These statements reflect current expectations and projections based on available data, historical patterns, and various assumptions. Words such as 'expects,' 'anticipates,' 'projects,' 'believes,' 'forecasts,' and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future outcomes and are subject to inherent uncertainties, including changes in consumer preferences, economic conditions, technological advancements, and competitive dynamics. Actual results may differ materially from those expressed or implied in these statements. While we strive to base our insights on reliable data and sound methodologies, we undertake no obligation to update any forward-looking statements to reflect future events or circumstances, except to the extent required by applicable law.

© 2026 Nielsen Consumer LLC. All Rights Reserved.

Frequently Asked Questions

Q: What is changing with Spaceman®?

A: NIQ is investing in Spaceman to deliver a more scalable, cloud-enabled, and AI-powered merchandising solution. The latest enhancements combine cloud-based delivery, AI/ML-powered capabilities, and enhanced automation to help retailers and manufacturers plan faster, execute better, and grow smarter while turning merchandising decisions into measurable business outcomes.

Q: Why is NIQ investing in Spaceman?

A: Retailers are under increasing pressure to localize assortments, execute consistently across stores, and respond more quickly to changing shopper behavior. These investments are designed to reduce manual planning effort, help retailers scale localized merchandising decisions, and improve execution across large store networks.

Q: What makes the latest evolution of Spaceman different?

A: The latest evolution brings conversational AI, planogram automation, modeling, compliance measurement, and cloud-based access together within the Spaceman merchandising workflow. This enables retailers to move more efficiently from planning to store-specific execution while scaling decisions across their store networks.

Q: How does Spaceman help retailers?

A: Spaceman helps retailers create and maintain localized, store-specific planograms at scale, reduce manual planning effort, and improve visibility into merchandising execution and compliance. This helps teams respond more effectively to local market conditions, assortments, and shopper behavior while delivering greater consistency across their store networks.

Q: How does cloud-based access support Spaceman clients?

A: NIQ-managed Azure hosting enables clients to operate Spaceman on NIQ-managed cloud infrastructure, reducing reliance on internal IT resources while improving scalability, deployment speed, and overall platform performance.

Q: What AI capabilities are included in Spaceman?

A: NIQ Optiq brings conversational AI into Spaceman, enabling merchandising teams to use natural-language requests to create and optimize planograms with less manual effort. Spaceman also uses AI and machine learning to support planogram automation and compliance measurement, helping retailers localize merchandising at scale and identify execution gaps across stores.

Q: What is NIQ Optiq in Spaceman?

A: NIQ Optiq brings conversational AI into Spaceman, enabling users to translate natural-language requests into planogram actions. It works with the data already managed within Spaceman and its existing automation and machine learning capabilities to help merchandising teams create and optimize planograms with less manual effort.

Q: Who can benefit from Spaceman?

A: Spaceman is designed for retailers looking to modernize merchandising operations, improve planogram creation and execution, reduce manual effort and IT complexity, and scale localized, data-driven merchandising decisions across their store networks.

Q: What types of business decisions can Spaceman support?

A: Spaceman supports decisions across assortment planning, space planning, store-specific planogram creation, merchandising execution, compliance measurement, and category management. By connecting planning and execution, Spaceman helps retailers make more localized and consistent merchandising decisions across their store networks.

Q: How does Spaceman support NIQ's broader strategy?

A: These investments reflect NIQ's broader commitment to embedding trusted AI across retail workflows and delivering cloud-enabled solutions that help retailers move more seamlessly from planning to execution. By connecting intelligent automation, merchandising decisions, and execution measurement, NIQ is helping retailers drive greater efficiency and consistency across their operations.

Q: Is this the final phase of Spaceman's evolution?

A: No. The latest enhancements represent the next step in NIQ's ongoing investment in Spaceman. NIQ will continue to evolve the platform to help retailers simplify merchandising, improve execution, and respond more effectively to changing market conditions.

NIQ-GENERAL

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261001493563/en/

Permalink

https://www.aetoswire.com/en/news/54613412

Contacts

Media contact: Julia Mayer

julia.mayer@nielseniq.com

 

LISTERINE® Launches Oral Care Counts This World Smile Day as Oral Disease Cases Rise to 3.73 Billion

 SUMMIT, N.J. - Thursday, 01. October 2026 AETOSWire Print 

Global research shows oral disease case numbers rose more than 3% over four years, as researchers warn that progress is too slow to meet the WHO’s 2030 target.

This World Smile Day, LISTERINE® is launching Oral Care Counts – a multiyear education and advocacy initiative showing why oral health is an essential part of overall health and how practical daily habits, including a three-step oral care routine of brushing, flossing and rinsing, can support better oral health.

 

(BUSINESS WIRE)--Nearly half the world’s population is affected by oral disease – and the number of cases is rising. This World Smile Day, LISTERINE® is launching Oral Care Counts – a multiyear education and advocacy initiative showing why oral health is an essential part of overall health and how practical daily habits, including a three-step oral care routine of brushing, flossing and rinsing, can support better oral health. The multiyear education and advocacy campaign is designed to help more people understand the essential role oral health plays in overall health and wellbeing, and how realistic daily habits can make prevention more achievable.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001163338/en/

Oral Care Counts aims to bring together healthcare professionals, advocates, policymakers, community organizations, and consumers to raise understanding of oral health as an essential part of overall health and wellbeing. The initiative encourages people to look beyond the smile, consider the health of the whole mouth and understand the role that brushing, flossing and, where appropriate, an essential-oil mouthrinse can play within a more complete daily routine.

As the #1 Dentist Recommended Mouthwash Brand* in the United States, LISTERINE® is bringing more than a century of oral health research and innovation to a simple but important belief: healthy mouths are an essential part of healthy lives.

A growing global challenge – and a narrowing window for action

The systematic analysis, published in The Lancet Public Health, found that cases of the main oral conditions rose 3.07% in four years. These conditions include untreated tooth decay, severe periodontitis, and total tooth loss.¹

The WHO’s Global Oral Health Action Plan calls for a 10% relative reduction in the combined prevalence of the main oral diseases and conditions by 2030, compared with 2019.² A growing and aging global population is a key factor behind rising case numbers, while other pressures are more localized. In many communities, inadequate fluoride exposure, high-sugar foods and limited access to oral health services continue to sustain the wider burden.³ These pressures underline the need for action at several levels – from access to professional care and public health measures, to effective daily self-care such as brushing, flossing and using a clinically proven essential-oil mouthrinse.

Prevention has to work in the real world

JoAnn Gurenlian, RDH, MS, PhD, AAFAAOM, FADHA said:

“Oral health doesn’t exist in isolation: it’s an essential part of overall health and wellbeing. These alarming figures underline a health challenge whose consequences extend far beyond the mouth.

“Brushing twice daily with fluoride toothpaste and flossing are the foundations. For people who need additional support, adding an essential-oil mouthrinse can be a straightforward 30-second third step, completing the routine with clinically demonstrated benefits beyond brushing and flossing alone.⁴–⁶

Making oral care count every day

Oral Care Counts combines education, advocacy, and collaboration to make oral health easier to understand, elevate it as an essential part of overall health and wellbeing, and make everyday prevention more achievable. It will also help people understand the role that mouthrinse can play within a complete oral care routine.

Oral Care Counts will:

Elevate awareness of oral health as an essential part of overall health and wellbeing, and of the role mouthrinse can play within a complete oral care routine, via webinars, training sessions and chairside guides developed for the American Dental Hygienists Association

Support healthcare professionals, including pharmacists, with evidence-based education and practical resources through partnerships such as our pharmacy upskilling program with retail grocery and pharmacy chain, Meijer, and the National Community Pharmacists Association - as we work to reach more patients/consumers in rural communities, and educate them on the importance of preventative oral care.

Help people strengthen daily oral care habits and improve access to preventive information and care through partnerships with organizations such as the National Rural Health Association and Young Minds Inspired.

The campaign reflects the belief that oral care matters for more than fresh breath or appearance. Oral health is an essential part of overall health and wellbeing: a healthy mouth supports everyday comfort, confidence and quality of life, and caring for the mouth is an important part of caring for the whole person.

Brushing and flossing remain essential: where appropriate, adding a LISTERINE® essential-oil mouthrinse as the third step in a complete routine can provide clinically demonstrated additional benefits beyond brushing and flossing alone.⁵˒⁶

Oral Care Counts will be activated in the United States and other key markets globally, with a particular focus on prevention, affordability and access.

Building on a legacy of oral health leadership

For more than 100 years, LISTERINE® has advanced research and innovation to support whole-mouth health. Further strengthening its commitment to meeting evolving consumer preferences, the brand launched a range of intensities earlier this year and, most recently, new LISTERINE® Whitening mouthwash. Designed to fit seamlessly into the daily three-step oral care routine of brushing, flossing, and rinsing, this alcohol-free and peroxide-free mouthwash delivers a superior clean, fresh breath and effective whitening in a gentle formula that strengthens teeth without sensitivity-causing ingredients.

Trusted by more than one billion people worldwide, the brand continues to champion science-backed solutions that help consumers maintain healthier oral care routines every day.

“Through Oral Care Counts, we are bringing together practical education, professional support, and achievable daily habits to help more people take control of their oral health,” said Holly Turner, Global Vice President, LISTERINE® & BAND-AID®. “That includes helping people understand how brushing, flossing and, where appropriate, a clinically proven essential-oil mouthrinse can work together as a complete three-step routine. World Smile Day is the right moment to start the bigger conversation and show why caring for the mouth is an important part of caring for the whole person.”

To learn more about Oral Care Counts, visit Listerine.com/OralCareCounts

About Oral Care Counts

Oral Care Counts is LISTERINE®’s multiyear education and advocacy initiative, developed to elevate oral health as an essential part of overall health and help more people take control of it through practical, effective daily habits, including the role of a clinically proven essential-oil mouthrinse within a complete three-step routine where appropriate.

The initiative engages healthcare professionals, advocates, policymakers, community organizations, and consumers to support evidence-based education, strengthen everyday self-care, increase understanding of the role mouthrinse can play within a complete routine, and improve access to oral health information and preventive care.

For further information, visit Listerine.com/OralCareCounts

About LISTERINE®

For more than a century, LISTERINE® has advanced research and innovation to support oral health. Studies involving LISTERINE® have appeared in hundreds of peer-reviewed publications, supporting its longstanding commitment to science-backed oral care. LISTERINE® is the #1 Dentist Recommended Mouthwash Brand* in the United States and is a brand of Kenvue Brands LLC, a subsidiary of Kenvue Inc.

*IQVIA ProVoice Survey, February 2026 (United States).

About World Smile Day

World Smile Day® is observed annually on the first Friday in October. It was created in 1999 by Harvey Ball, the commercial artist who designed the original smiley face in 1963, as a day dedicated to smiles, kindness and goodwill. Its enduring call to action is: “Do an act of kindness. Help one person smile.” Following Harvey Ball’s death in 2001, the Harvey Ball World Smile Foundation was established to continue his legacy and serves as the official sponsor of World Smile Day®. In 2026, World Smile Day® falls on Friday, October 2.

References

GBD 2023 Oral Disorders Collaborators. Global and regional progress towards reduced burden of oral conditions between 2019 and 2023: a systematic analysis for the Global Burden of Disease Study 2023. The Lancet Public Health. 2026;11(9e630–e641. doi:10.1016/S2468-2667(26)00143-X. https://pubmed.ncbi.nlm.nih.gov/42612648/

World Health Organization. Global strategy and action plan on oral health 2023–2030. Geneva: World Health Organization; 2024. https://www.who.int/publications/i/item/9789240090538

World Health Organization. Oral health. Fact sheet. Updated March 17, 2025. https://www.who.int/news-room/fact-sheets/detail/oral-health

Chapple ILC, Van der Weijden F, Doerfer C, Herrera D, Shapira L, Polak D, et al. Primary prevention of periodontitis: managing gingivitis. Journal of Clinical Periodontology. 2015;42(Suppl 16) :S71–S76. doi:10.1111/jcpe.12366.

Araujo MWB, Charles CA, Weinstein RB, McGuire JA, Parikh-Das AM, Du Q, et al. Meta-analysis of the effect of an essential oil-containing mouthrinse on gingivitis and plaque. Journal of the American Dental Association. 2015;146(8):610–622. doi:10.1016/j.adaj.2015.02.011.

Sharma N, Charles CH, Lynch MC, Qaqish J, McGuire JA, Galustians JG, et al. Adjunctive benefit of an essential oil-containing mouthrinse in reducing plaque and gingivitis in patients who brush and floss regularly: a six-month study. Journal of the American Dental Association. 2004;135(4):496–504. doi:10.14219/jada.archive.2004.0217.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261001163338/en/

Permalink

https://www.aetoswire.com/en/news/54613730

Contacts

Media Contacts

Annette Reichel

areiche1@kenvue.com

917-664-7114

Meghan Harding

mhardin1@kenvue.com

904-417-3336

 

Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates

INCHEON, Korea & TEL AVIV, Israel - Thursday, 01. October 2026

The agreement covers SB41, a potential biosimilar candidate referencing Fasenra® (benralizumab), and SB44, a potential biosimilar candidate referencing Ilaris® (canakinumab) with an option for 4 additional assets

The partnership will cover development and commercialization in the United States, Europe, and Canada, with an option to expand to other territories

The partnership brings together Samsung Bioepis’ development, regulatory and manufacturing capabilities with Teva’s global commercial reach to advance the investigational biosimilar candidates and help bring additional important treatment options to patients worldwide

 

(BUSINESS WIRE) -- Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the companies have entered into a global license, development, and commercialization agreement for up to six potential biosimilar candidates, with two confirmed investigational biosimilar candidates, SB41, a biosimilar candidate referencing Fasenra®1 (benralizumab), and SB44, a biosimilar candidate referencing Ilaris®2 (canakinumab).

Under the terms of the agreement, Samsung Bioepis will be responsible for the development, regulatory registration, and manufacture of the biosimilars, while Teva will be responsible for commercialization in global markets, including the United States (U.S.), Europe, and Canada. The companies have agreed to an option for expanding the partnership to other territories.

This agreement reinforces the long-standing and successful partnership between Samsung Bioepis and Teva, which has already resulted in the successful commercialization of EPYSQLI® (eculizumab-aagh) in the U.S. The companies have also expanded that agreement further to include OPUVIZ® (aflibercept) in Canada. The expanded collaboration reflects a shared approach to combining complementary capabilities for broadening access to biosimilar medicines across global markets.

“We are thrilled to expand our successful partnership with Teva with these new biosimilar candidates. This agreement marks another milestone in our shared journey to improve patient access to life-changing medicines,” said Kyung-Ah Kim, President and Chief Executive Officer at Samsung Bioepis. “At Samsung Bioepis, we will continue to demonstrate our enduring commitment to biosimilars by further strengthening our pipeline and widening their availability for patients and healthcare systems across the world.”

Richard Francis, President and CEO of Teva said, “Biosimilars are an increasingly important part of our Pivot to Growth strategy and our ambition to transform into a leading biopharmaceutical company. This global multi-product agreement is a significant step in scaling our biosimilars business, adding greater breadth to our pipeline and building on the strong foundation we have established with Samsung Bioepis in the U.S. By combining a strong and growing portfolio and our excellent global commercial capabilities, we are strengthening our leadership position in biosimilars and our ability to bring more treatment options to patients around the world.”

About Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. As a wholly owned subsidiary of Samsung Epis Holdings (KRX: 0126Z0), Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology. For more information, please visit www.samsungbioepis.com and follow us on LinkedIn and X.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit https://www.tevapharm.com.

Teva Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “may,” “project,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully execute the license, development and commercialization agreement with Samsung Bioepis; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generic medicines; and other factors discussed in our Quarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ending December 31, 2025, including in the section captioned “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

1 Fasenra is a trademark of AstraZeneca AB.

2 Ilaris is a trademark of Novartis AG.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261001835078/en/

Permalink

https://www.aetoswire.com/en/news/0110202657731

Contacts

MEDIA CONTACT

Samsung Bioepis Media Inquiries:

Anna Nayun Kim, nayun86.kim@samsung.com

Yoon Kim, yoon1.kim@samsung.com

Teva Media Inquiries:

TevaCommunicationsNorthAmerica@tevapharm.com

Teva Investor Relations Inquiries:

TevaIR@Tevapharm.com

Global Health Leaders to Convene at Abu Dhabi Future Health Summit 2026

 Abu Dhabi Future Health Summit will convene leaders across healthcare, science, technology, policy, and investment from 20-22 October at ADNEC Centre Abu Dhabi

Under the 2026 theme ‘To Sense is to Predict’, the Future Health Summit will examine how greater health insight can enable earlier intervention and better outcomes

AstraZeneca CEO Sir Pascal Soriot, Isomorphic Labs President Mr. Max Jaderberg, Amref Health Africa Group CEO Dr. Githinji Gitahi, and Health Ministers from Kosovo, Montenegro, Serbia and Colombia are among more than 130 Forum speakers, with participation expected from 100 countries

 

(BUSINESS WIRE)--Global leaders across healthcare, science, technology, policy, and investment will convene at the Abu Dhabi Future Health Summit from 20 to 22 October 2026 to examine how health systems can better anticipate risk and enable earlier intervention as advances in AI, genomics, diagnostics, and health data create new possibilities for understanding health risks earlier.

As health systems respond to the growing burden of chronic disease and the need to help people live longer in good health, the ability to identify changing health risks and act sooner is becoming increasingly important. Hosted by Future Health – A Global Initiative by Abu Dhabi and the Department of Health – Abu Dhabi, the Future Health Summit will be held under the theme 'To Sense is to Predict', exploring the global shift from reactive models of care towards earlier prediction, prevention, and personalised intervention.

Future Health is already translating this ambition into year-round activity. Its inaugural Future Health Challenge received 393 submissions from 68 countries with solutions already present in international communities. Additionally, the platform has released the Future of Longevity and Future of Healthy Living whitepapers, and joined the MIT Koch Institute for Integrative Cancer Research’s BioConvergence Cancer Alliance as a Founding Member. The Future Health Summit will build on this work, bringing the Future Health community together in Abu Dhabi to advance further collaboration and implementation.

With 130 Forum speakers and more than 175 exhibitors, with representation expected from 100 countries, the Summit will bring together expertise from a wide range of health systems and settings to examine how emerging approaches can work across different populations and models of care.

Featured Forum speakers include:

His Excellency Mansoor Al Mansoori, Chairman of the Department of Health – Abu Dhabi

Sir Pascal Soriot, CEO of AstraZeneca

Mr. Tim Schmid, EVP & Worldwide Chairman of Johnson & Johnson MedTech

Ms. Helga Fogstad, Director of Health, UNICEF

Mr. Will Ahmed, Founder & CEO of WHOOP

Mr. Tom Hale, CEO of ŌURA

Dr. Christine Yuan Huang, Founder & CEO of Quantum Life

Mr. Max Jaderberg, President of Isomorphic Labs

Dr. Ola Brown, Founding Partner of HealthCap Africa

Dr. Jayasree Iyer, CEO of Access to Medicine Foundation

Mr. Hugo Harper, Mission Director of a Healthy Life at Nesta

They will be joined by international ministers and government representatives. This global participation brings experience of national health systems and organisations to the discussions in Abu Dhabi, reflecting the reach of the Future Health community.

Her Excellency Dr Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, said: “The ability to understand health risk earlier can have a measurable impact on how health systems serve their populations. As advances in science and technology give us greater insight into health, the priority is to translate that insight into earlier action that can improves outcomes and help people live more years in good health.

“Global collaboration is fundamental to advancing this approach across different health systems and contexts. The Abu Dhabi Future Health Summit brings international expertise together with the capabilities we have built in Abu Dhabi, creating opportunities compare experience across health systems and examine how new approaches can work in practice. Abu Dhabi provides a real-world environment where that global exchange can connect directly with implementation at population scale,” she added.

At the core of the Summit is the Forum, which will feature keynotes, C-suite conversations, and public-private dialogues involving leaders from across the global health ecosystem. The Forum will explore ‘To Sense is to Predict’ at three interconnected levels - individual, health system, and population - with discussions spanning Future Health’s four thematic focus areas: Longevity and Precision Medicine; Digital Health & AI; Health System Resilience & Sustainability; and Investment in Life Sciences.

Alongside the Forum, the Global Exhibition will bring together exhibitors from across healthcare, technology, life sciences, and investment, showcasing innovations and capabilities shaping the future of health. A programme of Side Events will provide further opportunities for focused dialogue and collaboration.

The Abu Dhabi Future Health Summit is the annual flagship gathering of Future Health – A Global Initiative by Abu Dhabi, a year-round platform for global collaboration and transformative health innovation. Throughout 2026, Future Health has advanced the ‘To Sense is to Predict’ agenda through international dialogues, research and impact initiatives designed to move ideas towards real-world application.

A full list of Forum speakers, which will continue to be updated in the lead up to the event, is available on the Future Health website.

Register as a visitor: Future Health Summit Visitor Registration

Media registrations are welcome at: Future Health Summit Media Registration

About Future Health – A Global Initiative by Abu Dhabi

Future Health is a year-round platform for global collaboration and transformative health innovation, held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council.

Bringing together health researchers, policymakers, business leaders, investors and entrepreneurs from across disciplines and geographies, Future Health drives collective action to strengthen health systems and unlock longer, healthier lives for all.

Through a year-round programme of research insights, publications, impact initiatives, Challenges, R&D funding, and cross-sector convenings, Future Health advances progress across four focus areas: longevity and precision medicine, health systems and sustainability, digital health and AI, and investment in life sciences.

Future Health is curated and convened by the Department of Health – Abu Dhabi and its Founding Partners PureHealth, M42, Institute for Healthier Living Abu Dhabi, and Mubadala Bio. Mediclinic Middle East serves as Strategic Partner and Burjeel Holdings as Associate Partner.

For more information, visit www.futurehealthinitiative.ae⁠ and follow Future Health on: X, Instagram, LinkedIn and Facebook.

About the Department of Health – Abu Dhabi (DoH):

The DoH is the regulatory body of the healthcare sector at the Emirate of Abu Dhabi and ensures excellence in healthcare by monitoring the health status of the population. DoH defines the strategy for the health system, monitors and analyses the health status of the population and performance of the system. In addition, DoH shapes the regulatory framework for the health system, inspects against regulations, enforces standards, and encourages adoption of world-class best practices and performance targets by all healthcare service providers in the Emirate. DoH also drives programmes to increase awareness and adoption of healthy living standards among the residents of the Emirate of Abu Dhabi in addition to regulating scope of services, premiums and reimbursement rates of the health system.

For further information on DOH, visit https://www.doh.gov.ae/ and follow on Twitter, Instagram, Facebook, LinkedIn and YouTube.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261001283179/en/

Permalink

https://aetoswire.com/en/news/54614269

Contacts

 

Media Enquiries

For media enquiries, interview requests and accreditation opportunities, please contact: media@futurehealthinitative.ae

MidOcean Concludes 2026 Equity Raise, Securing More Than $4 Billion of Equity Commitments to Accelerate Global LNG Growth Strategy

 (BUSINESS WIRE) -- MidOcean Energy ("MidOcean" or the "Company"), a liquefied natural gas (LNG) company formed and managed by EIG, today announced the conclusion of its 2026 equity capital raise, securing more than $4 billion of closed and pending commitments over the last 12 months from new strategic and institutional investors, as well as significant re-ups from existing investors. The capital committed significantly exceeded the Company's original target of $2 billion, reflecting continued confidence in MidOcean's strategy, portfolio, team and long-term growth outlook.

The raise includes commitments from strategic investors, sovereign-linked institutions and financial investors. Among the new investors are the Private Department of Sheikh Mohammed bin Khalid Al Nahyan, Idemitsu Kosan, NYK Line (through Diamond Gas MidOcean), The Arab Energy Fund, Shizuoka Gas and certain Korean institutional investors.

The proceeds are expected to enhance MidOcean's balance sheet flexibility and position the Company to pursue a pipeline of LNG growth opportunities encompassing both cash flowing and development assets. MidOcean has assembled an LNG portfolio spanning Canada, Australia, the U.S., and Latin America and continues to evaluate accretive opportunities consistent with its disciplined investment approach.

R. Blair Thomas, Chairman of MidOcean and Chief Executive Officer of EIG, said:

"The progress achieved in this capital raise represents a major milestone for MidOcean and supports our strategy of building a scaled, diversified and resilient global LNG platform. We are pleased to welcome a distinguished group of new investors and thank our existing shareholders for their continued support and confidence."

"We believe LNG will continue to play an essential role in supporting energy security and global economic growth, and that MidOcean is well positioned to benefit from these long-term market fundamentals. Current events also highlight the importance of geographic diversification with the ability to reliably serve clients from multiple delivery points."

De la Rey Venter, Chief Executive Officer of MidOcean, said:

"In just a few years, MidOcean has grown from concept to a fully integrated global LNG platform, and this capital raise further strengthens our financial flexibility and positions us to continue advancing our robust growth strategy. We have built a high-quality LNG portfolio with strong cash flow characteristics and meaningful growth optionality, and we are well positioned to move decisively on the pipeline of opportunities we have identified. We look forward to building on this momentum and creating value for our investors."

About EIG

EIG is a leading institutional investor in the global energy and infrastructure sectors with $27.1 billion in assets under management as of June 30, 2026. EIG specializes in private investments in energy and energy-related infrastructure on a global basis. During its 44-year history, EIG has committed over $55 billion to the energy sector through 429 projects or companies in 44 countries on six continents. EIG’s clients include many of the leading pension plans, insurance companies, endowments, foundations and sovereign wealth funds in the U.S., Asia and Europe. EIG is headquartered in Washington, D.C. with offices in Houston, London, Sydney, Rio de Janeiro, Hong Kong and Seoul. For additional information, please visit EIG’s website at www.eigpartners.com.

About MidOcean Energy

MidOcean Energy, a pure play LNG company formed and managed by EIG, seeks to build a diversified, resilient, cost- and carbon-competitive global LNG portfolio. It reflects EIG’s belief in LNG as a critical element of a lower-carbon, competitive and more secure global energy system. MidOcean has established a platform with interests in LNG projects across the US, Latin America, Canada and Australia, supported by a global footprint including an LNG shipping and marketing office in Singapore and corporate headquarters in London. For additional information, please visit www.midoceanenergy.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261001738066/en/

Permalink

https://www.aetoswire.com/en/news/0110202657733

Contacts

EIG/MidOcean Contact Information

FGS Global

Kelly Kimberly / Brandon Messina

+1 212-687-8080

EIG@fgsglobal.com

 

Andersen Global Enhances Pakistan Legal Presence with New Member Firm

 SAN FRANCISCO - Thursday, 01. October 2026 AETOSWire Print 

(BUSINESS WIRE) -- Andersen Global strengthens its legal presence in Pakistan as Samdani & Qureshi, a collaborating firm since 2021, rebrands to Andersen Legal in Pakistan and is the latest member firm to join the organization.

Headquartered in Islamabad, Andersen Legal in Pakistan advises domestic and international clients, including businesses, investors, financial institutions, public sector entities, development organizations, and individuals, on legal, commercial, and regulatory matters. The firm also handles arbitration and dispute resolution, advising on complex transactions, investments, finance, projects, and contentious matters in Pakistan and across borders.

“Our approach is grounded in senior attention, clear communication, and disciplined analysis, with a focus on delivering advice that clients can put into action,” said Nudrat Ejaz Piracha, partner at Andersen Legal in Pakistan. “Joining Andersen Global enables us to build on this approach by drawing on additional capabilities and perspectives, while continuing to help clients manage risk, preserve value, and support long-term growth.”

“As businesses pursue investment and growth opportunities in Pakistan, they increasingly require legal counsel that understands both the local environment and the broader commercial context,” said Mark L. Vorsatz, global chairman and CEO of Andersen. “Andersen Legal in Pakistan brings a broad legal practice and an experienced team that will further strengthen our capabilities and support clients throughout the Southern Asia region.”

Andersen Global is an international association of legally separate, independent member firms comprised of tax, legal, and valuation professionals around the world. Established in 2013 by U.S. member firm Andersen Tax LLC, Andersen Global now has more than 50,000 professionals worldwide and a presence in over 1,000 locations through its member firms and collaborating firms.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261001015747/en/

Permalink

https://www.aetoswire.com/en/news/0110202657743

Contacts

Megan Tsuei

Andersen Global

415-764-2700

 

Moody’s Analytics and Allvue Launch Credit Risk Model to Identify Early Signs of Borrower Stress in Private Credit

NEW YORK - Thursday, 01. October 2026

Moody’s Analytics EDF-X Private Credit Model, powered by Allvue data, gives investors and lenders an earlier view of borrower stress in a rapidly growing market

(BUSINESS WIRE) -- Moody’s Corporation (NYSE: MCO), a global leader in risk assessment and credit analytics, and Allvue Systems, LLC, a leading technology and data provider for private capital markets, today announced the launch of the Moody’s Analytics EDF-X Private Credit Model, a new forward-looking credit risk model purpose-built for the private credit market. Built on Moody’s deep credit expertise and Allvue’s private credit performance data, the model identifies early signals of borrower stress, such as covenant waivers and payment-in-kind arrangements, well before they show up as missed payments or defaults.

Moody’s projects private credit to approach $4 trillion in assets by 2030, and investors and lenders are increasingly seeking earlier visibility on where risk is building across portfolios. Unlike public credit markets where participants have the benefit of access to published credit ratings, financial disclosures, and transparent pricing, private credit often relies on proprietary credit assessments with limited comparability across positions. Moody’s and Allvue are collaborating to bring greater transparency and insight to the market.

The model draws on de-identified private credit borrower performance data contributed by Allvue. Complementing the existing Moody’s Analytics credit risk models, which reflect the performance of private companies across a broad range of lending markets, it is the first Moody’s model calibrated directly on observed private credit performance, giving it a view of borrower credit risk that reflects the specific dynamics of the asset class. The model separately estimates the likelihood of hard credit events, such as missed payments, and of the soft credit events that often precede them.

“In private credit, the signals that matter often emerge before a missed payment or default,” said Christina Kosmowski, CEO of Moody’s Analytics. “By combining Allvue’s private market data with Moody’s credit intelligence, we can help customers identify borrower stress earlier and bring greater transparency and insight to a rapidly growing market.”

More than 1,000 private capital firms use Allvue solutions, directly or through their fund administrators. Allvue has built one of the industry’s most comprehensive datasets of private credit performance, along with the data and analytics capability that turns it into products the market can use. The data Allvue is contributing to Moody’s is de-identified and contractually governed, and no individual firm is identifiable in it.

“Private credit has grown faster than the infrastructure built to monitor it, and we built a data and analytics business to close that gap,” said Marc Scheipe, CEO of Allvue. “Pairing Allvue’s data with Moody’s analytical depth gives institutions an independent, third-party evaluation of risk across their direct lending portfolios, and that is the kind of transparency that helps this market stay informed.”

The model gives market participants a view of both borrower fundamentals and emerging credit deterioration. It supports portfolio monitoring, manager evaluation, investment selection, and capital allocation, and is now available to customers of both firms through the Moody’s Analytics EDF-X API.

The model joins the growing Moody’s Analytics suite of private credit solutions, including EDF-X CreditGradient, which expresses model-based credit risk signals for unrated borrowers. These are analytical models and are distinct from the credit ratings and other services provided to issuers in the private credit market by Moody’s Ratings, the credit rating agency.

For more than 115 years, Moody’s has helped markets understand and navigate credit risk. Moody’s is bringing that expertise together with new sources of private market data and analytics to provide greater transparency and intelligence as private credit continues to grow.

For more information, visit https://moodys.com/allvue.

About Moody’s Corporation

In a world shaped by increasingly interconnected risks, Moody’s (NYSE: MCO) data, insights, and innovative technologies help customers develop a holistic view of their world and unlock opportunities. With a rich history of experience in global markets and a diverse workforce of approximately 16,000 across more than 40 countries, Moody’s gives customers the comprehensive perspective needed to act with confidence and thrive. Learn more at moodys.com.

About Allvue Systems

Allvue Systems is the leading technology and data platform for private markets, helping investment managers, fund administrators, and other market participants make private markets more transparent, efficient, and connected. Allvue’s AI-powered platform connects data and workflows across the private investment lifecycle, combining mission-critical software with differentiated private markets data and analytics — drawn from de-identified, anonymized, and aggregated data across its platform — to automate complex processes, deliver actionable insights, and enable better-informed decisions.

“Safe harbor” statement under the Private Securities Litigation Reform Act of 1995

Certain statements contained in this document are forward-looking statements and are based on future expectations, plans and prospects for Moody’s business and operations that involve a number of risks and uncertainties. Such statements involve estimates, projections, goals, forecasts, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those contemplated, expressed, projected, anticipated or implied in the forward-looking statements. Stockholders and investors are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements and other information in this document are made as of the date hereof, and Moody’s undertakes no obligation (nor does it intend) to publicly supplement, update or revise such statements on a going-forward basis, whether as a result of subsequent developments, changed expectations or otherwise, except as required by applicable law or regulation. Factors, risks and uncertainties as well as other risks and uncertainties that could cause Moody’s actual results to differ materially from those contemplated, expressed, projected, anticipated or implied in the forward-looking statements are described in greater detail under “Risk Factors” in Part I, Item 1A of Moody’s annual report on Form 10-K for the year ended December 31, 2025, and in other filings made by the Company from time to time with the SEC or in materials incorporated herein or therein. Stockholders and investors are cautioned that the occurrence of any of these factors, risks and uncertainties may cause the Company’s actual results to differ materially from those contemplated, expressed, projected, anticipated or implied in the forward-looking statements, which could have a material and adverse effect on the Company’s business, results of operations and financial condition.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261001018709/en/

Permalink
https://www.aetoswire.com/en/news/0110202657740

Contacts

For Moody’s Communications:

Joe Mielenhausen
Moody’s Corporation
+1 212-553-1461
Joe.Mielenhausen@moodys.com

For Allvue Systems:

David Swanger
Allvue Systems
press@allvuesystems.com

NetApp Recognizes Winners of 2026 North America Partner Awards

 SAN JOSE, Calif. - 

NetApp commends partners for success in helping deliver NetApp solutions and services that address customer needs and industry trends

 

(BUSINESS WIRE)--NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced at NetApp INSIGHT 2026 the winners of its North America Partner Awards for Fiscal Year 2026 (FY’26). NetApp’s strategic partnerships aid in providing NetApp products and solutions to solve the business challenges of their joint customers.

The North America Partner Award winners have been instrumental in helping customers to build an Intelligent Data Infrastructure through the NetApp Platform, that can securely evolve and scale with their needs by driving sales of NetApp’s solutions and services. Each winning partner has demonstrated a thorough understanding of the NetApp portfolio and has proven their ability to leverage NetApp’s innovative solutions and services to give customers the confidence they need to overcome today’s biggest technology challenges.

“Now more than ever, we must empower customers with AI-ready data that is secure by default and built for hybrid environments so they can achieve their business outcomes,” said Alvaro Celis, Senior Vice President, Chief Commercial, Partner and Ecosystem Officer at NetApp. “This year’s FY26 NetApp North America Partner Award winners exemplify innovation and transformation in the AI era. They helped customers solve data-readiness challenges by using the NetApp Platform to access, manage, and activate data across hybrid multicloud environments—enabling them to tackle demanding tasks and solve complex problems. On behalf of NetApp, congratulations to all this year’s winners on their well-earned success.”

North America Partner Award Winners for NetApp FY’26

North America Partner of the Year: Recognizing overall NetApp FY’26 revenue, services capabilities, net-new account wins, and top rankings across product categories.

Winner: World Wide Technology

Distributor of the Year: Recognizing the distributor that drives significant year-over-year (YoY) growth in their NetApp partner ecosystem while exhibiting demonstrated value in operations, sales and technical enablement, marketing, and financial services.

Winner: Arrow Enterprise Computing Solutions Inc.

Growth Partner of the Year: Recognizing the ability to generate significant YoY growth in NetApp revenue across the portfolio.

Winner: General Datatech (GDT)

Flash Partner of the Year: Recognizing overall FY’26 flash revenue, significant YoY growth, and strategic account wins.

Winner: ePlus Inc.

New Account Acquisition Partner of the Year: Recognizing the highest number of net-new accounts to NetApp with focused sales efforts on helping customers achieve digital transformation with NetApp solutions.

Winner: SHI International

NetApp Keystone® Partner of the Year: Recognizing a strategic sales and marketing approach to driving significant growth of NetApp Keystone.

Winner: Insight Enterprises

AI Partner of the Year: Recognized for exceptional AI business performance, customer impact, and leadership in scaling AI solutions globally.

Winner: World Wide Technology

AI Go-to-Market Partner of the Year: Recognizing acceleration of AI adoption through innovative customer engagement, seller activation, and a differentiated AI go-to-market strategy.

Winner: CDW

Cloud Partner of the Year: Recognizing overall FY’26 cloud data services revenue and deploying a focused cloud digital transformation strategy that aligns with the NetApp cloud vision.

Winner: AHEAD

Canada Partner of the Year: Recognizing overall NetApp FY’26 revenue and alignment to the NetApp strategy in the Canadian market.

Winner: Calian (DGI)

SLED Partner of the Year: Recognizing robust sales efforts resulting in the highest overall SLED business while also driving net-new account acquisition and revenue wins.

Winner: CDW-G

USPS Partner of the Year: Recognizing overall NetApp FY’26 revenue and YoY growth in the U.S. Public Sector market.

Winner: CTG Federal, LLC

DoD Partner of the Year: Recognizing strong performance in the DoD space, propelled by dynamic customer relationships and a commitment to growth.

Winner: FCN Inc.

Intelligence Partner of the Year: Recognizing profound sales and technical expertise in the Intelligence space contributing to significant overall YoY percentage growth in the U.S. Public Sector.

Winner: FlyWheel Data, LLC

Civilian Partner of the Year: Recognizing a strategic approach to sales and marketing, paired with demand generation efforts resulting in significant net new account acquisition, and Civilian business growth.

Winner: ThunderCat Technology, LLC

Regional Partner Award Winners for FY’26

These awards recognize overall FY’26 revenue, YoY growth, strategic account wins, a significant focus on NetApp solutions, and participation in regional partnership activities.

Central Region Partner of the Year: Recognizing overall NetApp FY’26 revenue, services capabilities, net-new account wins, and top rankings across product categories in the Central region.

Winner: Xigent Solutions

Central Region SLED Partner of the Year: Recognizing robust sales efforts in the Central region resulting in the highest overall SLED business while also driving net-new account acquisition and revenue wins.

Winner: Insight Enterprises

East Region Partner of the Year: Recognizing overall NetApp FY’26 revenue, services capabilities, net-new account wins, and top rankings across product categories in the East region.

Winner: Pellera Technologies

East Region SLED Partner of the Year: Recognizing robust sales efforts in the East region resulting in the highest overall SLED business while also driving net-new account acquisition and revenue wins.

Winner: WebHouse, Inc.

West Region Partner of the Year: Recognizing overall NetApp FY’26 revenue, services capabilities, net-new account wins, and top rankings across product categories in the West region.

Winner: Trace3

West Region SLED Partner of the Year: Recognizing robust sales efforts in the West region resulting in the highest overall SLED business while also driving net-new account acquisition and revenue wins.

Winner: Trace3

"Our work with NetApp enables us to help customers build a foundation, not a patchwork, even in a changing market that demands enterprises move at an ever accelerating pace," said Bob Olwig, EVP Global Alliances at World Wide Technology. "Innovation comes down to who can most quickly leverage their data to get the insights they need to move with confidence. NetApp gives us the tools to provide secure, scalable, governed access to data wherever it lives, so our customers can lead in their markets."

NetApp provides its partners with the resources, training, support, and access to the expertise they need to solve their customers’ most complex data management challenges and expand their market share with a broader range of cloud-based solutions.

For more information on how to become a NetApp partner, visit: www.netapp.com/partners/#become

About NetApp

For more than three decades, NetApp has helped the world’s leading organizations navigate change – from the rise of enterprise storage to the intelligent era defined by data and AI. Today, NetApp is the Intelligent Data Infrastructure company, helping customers turn data into a catalyst for innovation, resilience, and growth.

At the heart of that infrastructure is the NetApp data platform – the unified, enterprise-grade, intelligent foundation that connects, protects, and activates data across every cloud, workload, and environment. Built on the proven power of NetApp ONTAP, our leading data management software and OS, and enhanced by automation through the AI Data Engine and AFX, it delivers observability, resilience, and intelligence at scale.

Disaggregated by design, the NetApp data platform separates storage, services, and control so enterprises can modernize faster, scale efficiently, and innovate without lock-in. As the only enterprise storage platform natively embedded in the world’s largest clouds, it gives organizations the freedom to run any workload anywhere with consistent performance, governance, and protection.

With NetApp, data is always ready – ready to defend against threats, ready to power AI, and ready to drive the next breakthrough. That’s why the world’s most forward-thinking enterprises trust NetApp to turn intelligence into advantage.

Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.

NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261001042306/en/

Permalink

https://www.aetoswire.com/en/news/54614259

Contacts

Media Contact:

Kenya Hayes

NetApp

kenya.hayes@netapp.com

Investor Contact:

Kris Newton

NetApp

kris.newton@netapp.com

Visa Data Shows Stablecoins Gaining Traction in Business Payments

 New Visa data shows nearly 17%1 of stablecoin-linked card volume is occurring across business and commercial card programs, underscoring growing adoption of stablecoins for settlement, treasury management and cross-border commerce.

 

(BUSINESS WIRE)--Today, Visa (NYSE: V) shared new data showing the growing adoption of stablecoins across business payments and commercial card programs, underscoring how stablecoins are increasingly being used as financial infrastructure.

The findings come as businesses, financial institutions and payment providers increasingly explore stablecoins for settlement, treasury management, payouts and cross-border commerce.

New Visa data shows:

Approximately 17% of stablecoin-linked card volume in FY26 year-to-date occurred across business and commercial card programs.

Visa today supports more than 160 stablecoin-linked card programs spanning consumer, business and commercial card activity. Payments volume across these programs has grown nearly 200% year over year.

Businesses are increasingly exploring stablecoins for settlement, treasury management, payouts and cross-border commerce.

"Businesses aren't looking for new payment technologies for the sake of innovation. They’re looking for trusted, reliable ways to move money," said Mark Nelsen, Global Head of Product, Commercial & Money Movement Solutions, Visa. "What's changing is that stablecoins are increasingly becoming part of the conversation around real business applications, from supplier payments and treasury operations to cross-border commerce."

The Shift from Trading to Payments

For years, stablecoins have been associated with trading activity within digital asset markets, helping users move between cryptocurrencies and transact on crypto exchanges.

Today, businesses are increasingly putting stablecoins to work for payments, treasury operations and liquidity management.

Recent industry research from Allium found that payments are now the fastest-growing stablecoin use case, with annual payments volume estimated between $401 billion and $527 billion. The largest business payment categories include service fees ($56 billion), payroll ($43 billion) and supplier payments ($28 billion)2. Among the payment flows analyzed, B2B payments had the highest cross-border share, with 43% of volume occurring across borders3.

Visa is seeing that trend reflected across its own ecosystem. In FY26 year-to-date, approximately 17% of stablecoin-linked card volume occurred across business and commercial card programs, reflecting growing interest in stablecoins for settlement, treasury management and cross-border commerce.

Supporting the Next Generation of Money Movement

Visa continues to expand its stablecoin capabilities across settlement, money movement and payment acceptance. Through initiatives spanning stablecoin settlement, Visa Direct pre-funding and payouts, Visa is helping connect stablecoin innovation into real-world payment flows.

About Visa

Visa (NYSE: V) is a world leader in digital payments, facilitating transactions between consumers, sellers, financial institutions and government entities across more than 200 countries and territories. Our mission is to connect the world through the most innovative, convenient, reliable and secure payments network, enabling individuals, businesses and economies to thrive. We believe that economies that include everyone everywhere, uplift everyone everywhere and see access as foundational to the future of money movement. Learn more at Visa.com.

 

1 VisaNet data, FY26 year-to-date. Business and commercial activity determined using Visa's internal card program classifications

2 Allium, State of Stablecoins and Payments, Sep 2026 | Allium

3 Allium, State of Stablecoins and Payments, Sep 2026 | Allium. Cross-border share based on Allium's analysis of payment flows for which geographic attribution was available.

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261001564721/en/

Permalink

https://aetoswire.com/en/news/54614021

Contacts

Media Contacts

press@visa.com

Jackie Dresch

Conor Febos